US Patent

US12496326 — Ophthalmic composition for treatment of dry eye disease

Method of Use · Assigned to Novaliq GmbH · Expires 2036-09-29 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition containing cyclosporine dissolved in 1-perfluorobutyl-pentane for treating dry eye disease.

USPTO Abstract

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Drugs covered by this patent

Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3627`	—	Sandimmune

Patent Metadata

Patent number: US12496326
Jurisdiction: US
Classification: Method of Use
Expires: 2036-09-29
Drug substance claim: No
Drug product claim: No
Assignee: Novaliq GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.